Phase II Trial of Neoadjuvant ALIMTA Plus Cisplatin Followed by Surgery and Radiation in the Treatment of Pleural Mesothelioma
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Event-free Survival (EFS)
A participant was defined event-free if they did not show a progressive disease (PD), did not die and did not discontinue the treatment early. Participants without assessment at 1-year (due to whatever reason) were considered as Not-Event-Free.
date of first dose of study drug to first observation of disease progression, death from any cause, discontinuation of treatment (up to 43 months)
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Italy: Ministry of Health